Liquet Technologies has the device that is going to be the next standard of care for cataract surgery.

In 2021, Liquet Technologies was formed and spun off from MED-LOGICS Inc. to take the novel cataract technology developed by MED-LOGIS, make the necessary advancements to the next iteration of the device, and introduce it to the global cataract market under the Liquet Technologies brand.

Over the next year, Liquet Technologies will roll out a standard device for cataract surgery, known as Phacoemulsification, called the WAVE Phaco. The device will be distributed in 43 countries to build the Liquet Technologies brand. Within the next two years, Liquet Technologies will introduce the CataPulse Enterprise, a novel cataract removal technology that uses less invasive energy than what’s currently used in developed countries.

The CataPulse Enterprise will utilize a novel, patented technology called High-Frequency Pulsed Vacuum, which will treat about 90% of cataract patients and use mechanical ultrasound as a feature of the device to treat the remaining 10% of patients that have the hardest types of cataracts. Most importantly, the CataPulse will virtually eliminate the risk of infection when performing cataract surgery on both eyes during the same surgical day, which is something that’s considered too risky with the current standard of care for cataract surgery. This will lower cost, increase capacity, and open the market to the 120 million people that are affected by cataracts.